摘要
目的:探讨依洛尤单抗联合诺迪康颗粒治疗老年冠心病的疗效及对血清淀粉样蛋白A(SAA)、生长刺激表达基因2蛋白(ST2)、载脂蛋白B(ApoB)/载脂蛋白A1(ApoA1)的影响。方法:选取150例老年冠心病患者,随机分为单一组(n=75,行依洛尤单抗治疗),联合组(n=75,行依洛尤单抗联合诺迪康颗粒治疗),比较两组临床疗效、心肌损伤指标、心脏超声相关指数及血清ST2、SAA、ApoB/ApoA1的水平。结果:治疗后,单一组的总有效率为72.00%,低于联合组的90.67%(P<0.05);治疗后,两组N末端B型利钠肽原(NT-proBNP)、半乳糖凝集素-3(Gal-3)及心肌肌钙蛋白I(cTnI)水平显著降低,且联合组低于单一组(均P<0.05);治疗后,两组左心室后壁厚度(LVPWT)、左心室质量指数(LVMI)、左心室短轴缩短率(FS)均降低,且联合组低于单一组,每搏输出量(SV)、心脏指数(CI)均升高,且联合组高于单一组(均P<0.05);治疗后,两组ST2、SAA、ApoB/ApoA1水平显著降低,且联合组低于单一组(均P<0.05)。结论:依洛尤单抗联合诺迪康颗粒对老年冠心病患者疗效显著,能有效减轻患者心肌损伤程度,促进心功能恢复,缓解机体内炎症反应,优化血脂谱。
Objective:To investigate the efficacy of ilozumab combined with Nordicon granules in the treatment of elderly coronary heart disease and its effects on serum amyloid A(SAA),growth stimulation gene 2 protein(ST2),Apolipoprotein B(ApoB)/Apolipoprotein A1(ApoA1).Methods:A total of 150 elderly patients with coronary heart disease were randomly divided into single group(n=75,treated with ilozumab)and combined group(n=75,treated with ilozumab and Nordicon granules).The clinical efficacy,myocardial injury index,cardiac ultrasound correlation index and serum ST2,SAA,ApoB/ApoA1 levels were compared between the two groups.Results:After treatment,the total effective rate of single group was 72.00%,which was lower than that of combined group 90.67%,the difference was statistically significant(P<0.05).After treatment,the levels of N-terminal B-type natriuretic peptide(NT-proBNP),galectin-3(Gal-3)and cardiac troponin I(cTnI)in 2 groups were significantly decreased,and the combined group was lower than the single group,the difference was statistically significant(all P<0.05).After treatment,the left ventricular posterior wall thickness(LVPWT),left ventricular mass index(LVMI)and left ventricular short axis shortening rate(FS)were decreased in both groups,and the stroke output(SV)and heart index(CI)were increased in combined group compared with single group,and the differences were statistically significant(all P<0.05).After treatment,the levels of ST2,SAA and ApoB/ApoA1 in the two groups were significantly decreased,and the combined group was lower than the single group,the difference was statistically significant(all P<0.05).Conclusion:Ilozumab combined with Nordican granules has significant effect on elderly patients with coronary heart disease,which can effectively reduce the degree of myocardial injury,promote the recovery of cardiac function,alleviate inflammation in the body,optimize blood lipid profile.
作者
甘建祥
孔肖寒
刘全海
GAN Jianxiang;KONG Xiaohan;LIU Quanhai(Department of Cardiovascular Medicine,Nanjing Hospital,Nanjing 210000,China;Department of Cardiovascular Medicine,Yangzhong People’s Hospital,Yangzhong 212200,China)
出处
《陕西医学杂志》
2025年第4期524-528,共5页
Shaanxi Medical Journal
基金
江苏省临床医学科技专项课题(BE2019610)。
